keyword
MENU ▼
Read by QxMD icon Read
search

Cancer related anemia

keyword
https://www.readbyqxmd.com/read/28915677/docetaxel-versus-docetaxel-plus-cisplatin-for-non-small-cell-lung-cancer-a-meta-analysis-of-randomized-clinical-trials
#1
Ang Li, Zhi-Jian Wei, Han Ding, Hao-Shuai Tang, Heng-Xing Zhou, Xue Yao, Shi-Qing Feng
OBJECTIVE: To compare the activity, efficacy and toxicity of docetaxel versus docetaxel plus cisplatin in patients with non-small-cell lung cancer. METHODS: A literature search was performed in the EMBASE, Medline, Cochrane Library, Web of Science, China National Knowledge Internet, Wan-fang databases. The trials that were found were then evaluated for eligibility. The Cochrane Collaboration's Review Manager software was used to perform the meta-analyses. RESULTS: Nine clinical trials including 1257 patients were included...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28913549/multicenter-phase-ii-study-of-capecitabine-plus-cisplatin-as-first-line-therapy-for-human-epidermal-growth-factor-receptor-2-negative-advanced-gastric-cancer-yokohama-clinical-oncology-group-study-ycog1107
#2
Kei Sato, Chikara Kunisaki, Takashi Kosaka, Ryo Takagawa, Masazumi Takahashi, Yusuke Izumisawa, Hiroshi Miyamoto, Sho Sato, Yusaku Tanaka, Naotaka Yamaguchi, Jun Kimura, Hidetaka A Ono, Hirochika Makino, Hirotoshi Akiyama, Itaru Endo
PURPOSE: S-1 plus cisplatin therapy is the recommended standard first-line regimen for human epidermal growth factor receptor 2 (HER-2)-negative advanced unresectable or recurrent gastric cancer (AGC) in the Japanese Gastric Cancer Treatment Guidelines. By contrast, capecitabine plus cisplatin (XP) therapy has been second-line therapy for these patients. This prospective study aimed to evaluate the efficacy and safety of XP as a first-line regimen for HER2-negative patients with AGC. METHODS: In this multicenter, open-label, phase II study, patients received cisplatin (80 mg/m(2) i...
September 14, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28895417/the-prognostic-value-of-pre-treatment-thrombocytosis-in-two-cohorts-of-patients-with-non-small-cell-lung-cancer-treated-with-curatively-intended-chemoradiotherapy
#3
G Holgersson, S BergstrOm, A Hallqvist, P Liv, J Nilsson, L WillEn, J Nyman, S Ekman, R Henriksson, M Bergqvist
Chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC). This treatment, however, offers only a small chance of cure and is associated with many side effects. Little research has been made concerning which patients benefit most/least from the treatment. The present study evaluates the prognostic value of anemia, leukocytosis and thrombocytosis at diagnosis in this treatment setting. In the present study, data were collected retrospectively for 222 patients from two different phase II studies conducted between 2002-2007 in Sweden with patients treated with chemoradiotherapy for stage IIIA-IIIB NSCLC...
September 12, 2017: Neoplasma
https://www.readbyqxmd.com/read/28882352/adult-spinal-deformity-national-trends-in-the-presentation-treatment-and-perioperative-outcomes-from-2003-to-2010
#4
Peter G Passias, Cyrus M Jalai, Nancy Worley, Shaleen Vira, Bryan Marascalchi, Shearwood McClelland, Virginie Lafage, Thomas J Errico
STUDY DESIGN: Retrospective review of a prospective database. OBJECTIVES: To investigate adult spinal deformity (ASD) surgery outcome trends on a nationwide scale using the Nationwide Inpatient Sample (NIS) from 2003 to 2010. METHODS: ASD patients ≥25 years from 2003 to 2010 in the NIS undergoing anterior, posterior, or combined surgical approaches were included. Fractures, 9+ levels fused, or any cancer were excluded. Patient demographics, hospital data, and procedure-related complications were evaluated...
September 2017: Spine Deformity
https://www.readbyqxmd.com/read/28858227/the-role-of-palb2-in-the-dna-damage-response-and-cancer-predisposition
#5
REVIEW
Thales C Nepomuceno, Giuliana De Gregoriis, Francisco M Bastos de Oliveira, Guilherme Suarez-Kurtz, Alvaro N Monteiro, Marcelo A Carvalho
The deoxyribonucleic acid (DNA) damage response (DDR) is a major feature in the maintenance of genome integrity and in the suppression of tumorigenesis. PALB2 (Partner and Localizer of Breast Cancer 2 (BRCA2)) plays an important role in maintaining genome integrity through its role in the Fanconi anemia (FA) and homologous recombination (HR) DNA repair pathways. Since its identification as a BRCA2 interacting partner, PALB2 has emerged as a pivotal tumor suppressor protein associated to hereditary cancer susceptibility to breast and pancreatic cancers...
August 31, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28838395/randomized-phase-ii-study-of-carboplatin-plus-irinotecan-versus-carboplatin-plus-amrubicin-in-patients-with-chemo-na%C3%A3-ve-extensive-stage-small-cell-lung-cancer-north-japan-lung-cancer-study-group-njlcg-0901
#6
Naoto Morikawa, Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Masao Harada, Yuka Fujita, Terufumi Katoh, Hiroshi Yokouchi, Hiroshi Watanabe, Kazuhiro Usui, Toshiro Suzuki, Jun Sakakibara-Konishi, Hiroki Nagai, Mariko Kanbe, Toshihiro Nukiwa
OBJECTIVE: Carboplatin-based regimens are the standard regimens for patients with extensive-stage small-cell lung cancer (ES-SCLC). However, the efficacies of these regimens are unsatisfactory. We previously identified carboplatin plus irinotecan (CI) and carboplatin plus amrubicin (CA) as promising new carboplatin-based regimens. Accordingly, we conducted a randomized phase II study to identify the appropriate regimen for future phase III trials. MATERIALS AND METHODS: Chemotherapy-naïve patients with ES-SCLC were randomly assigned to receive 4-6 cycles of carboplatin [area under the curve (AUC) 5...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28833205/preoperative-management-of-colorectal-cancer-induced-iron-deficiency-anemia-in-clinical-practice-data-from-a-large-observational-cohort
#7
MaríaJesús Laso-Morales, Carlos Jericó, Susana Gómez-Ramírez, Jordi Castellví, Lorenzo Viso, Inmaculada Roig-Martínez, Caridad Pontes, Manuel Muñoz
BACKGROUND: Preoperative anemia prevalence among colorectal cancer (CRC) patients is high and may adversely influence postoperative outcome. This study assesses the efficacy of a preoperative anemia managing protocol in CRC. STUDY DESIGN AND METHODS: This was a retrospective analysis of consecutive CRC resections at two Spanish centers (January 2012 to December 2013). Preoperative anemia was defined as a hemoglobin (Hb) level of less than 13 g/dL and treated with intravenous iron (IVI) or standard care (oral iron or no iron)...
August 21, 2017: Transfusion
https://www.readbyqxmd.com/read/28832976/a-phase-1-1b-trial-of-adi-peg-20-plus-nab-paclitaxel-and-gemcitabine-in-patients-with-advanced-pancreatic-adenocarcinoma
#8
Maeve A Lowery, Kenneth H Yu, David Paul Kelsen, James J Harding, John S Bomalaski, Danielle C Glassman, Christina M Covington, Robin Brenner, Ellen Hollywood, Adalberto Barba, Amanda Johnston, Kay Chia-Wei Liu, Xiaoxing Feng, Marinela Capanu, Ghassan K Abou-Alfa, Eileen M O'Reilly
BACKGROUND: ADI-PEG 20 is a pegylated form of the arginine-depleting enzyme arginine deiminase. Normal cells synthesize arginine with the enzyme argininosuccinate synthetase (ASS1); ADI-PEG 20 selectively targets malignant cells, which lack ASS1. METHODS: A single-arm, nonrandomized, open-label, phase 1/1B, standard 3 + 3 dose escalation with an expansion cohort of 9 patients at the recommended phase 2 dose (RP2D) was conducted. Patients who had metastatic pancreatic cancer, up to 1 line of prior treatment (the dose-escalation cohort) or no prior treatment (the expansion cohort), and an Eastern Cooperative Oncology Group performance status of 0 to 1 were included...
August 18, 2017: Cancer
https://www.readbyqxmd.com/read/28817371/phase-i-ii-trial-of-labetuzumab-govitecan-anti-ceacam5-sn-38-antibody-drug-conjugate-in-patients-with-refractory-or-relapsing-metastatic-colorectal-cancer
#9
Efrat Dotan, Steven J Cohen, Alexander N Starodub, Christopher H Lieu, Wells A Messersmith, Pamela S Simpson, Michael J Guarino, John L Marshall, Richard M Goldberg, J Randolph Hecht, William A Wegener, Robert M Sharkey, Serengulam V Govindan, David M Goldenberg, Jordan D Berlin
Purpose The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or refractory metastatic colorectal cancer. Patients and Methods Eligible patients with at least one prior irinotecan-containing therapy received labetuzumab govitecan once weekly at 8 and 10 mg/kg, or two times per week at 4 and 6 mg/km on weeks 1 and 2 of 3-week repeated cycles...
August 17, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28794648/cost-analysis-of-adverse-events-associated-with-non-small-cell-lung-cancer-management-in-france
#10
Christos Chouaid, Delphine Loirat, Emilie Clay, Aurélie Millier, Chloé Godard, Amira Fannan, Laurie Lévy-Bachelot, Eric Angevin
BACKGROUND: Adverse events (AEs) related to medical treatments in non-small cell lung cancer (NSCLC) are frequent and need an appropriate costing in health economic models. Nevertheless, data on costs associated with AEs in NSCLC are scarce, particularly since the development of immunotherapy with specific immune-related AEs. OBJECTIVE: To estimate the costs of grades 3 and 4 AEs related to NSCLC treatments including immunotherapy in France. METHODS: Grades 3 and 4 AEs related to treatment and reported in at least 1% of patients in Phase III clinical trials for erlotinib, ramucirumab plus docetaxel, docetaxel, pemetrexed plus carboplatin plus bevacizumab, platinum-based chemotherapies, nivolumab and pembrolizumab were identified...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28780045/sleeve-gastrectomy-with-duodenojejunal-end-to-side-anastomosis-in-the-treatment-of-type-2-diabetes-the-initial-experiences-in-a-chinese-population-with-a-more-than-4-year-follow-up
#11
Xiaojiao Ruan, Weijian Zhang, Huajie Cai, Ru Zheng, Feizhao Jiang, Hengliang Zhu
BACKGROUND: Gastric bypass has been thought to be associated with a risk of gastric cancer, particularly in Asia. Sleeve gastrectomy with duodenojejunal end-to-side anastomosis (SG-DJESA) was suggested to be a better-designed procedure to avoid this risk, and it also has other advantages. OBJECTIVE: We aimed to evaluate the clinical efficacy and feasibility of SG-DJESA in the treatment of nonobese patients with type 2 diabetes (T2D). SETTING: University Hospital, China...
July 14, 2017: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/28775205/therapy-related-hematological-malignancies-after-peptide-receptor-radionuclide-therapy-with-177-lu-dota-octreotate-incidence-course-predicting-factors-in-patients-with-gep-nets
#12
Hendrik Bergsma, Kirsten van Lom, Mark Konijnenberg, Boen Kam, Jaap Teunissen, Wouter de Herder, Eric Krenning, Dik Kwekkeboom
Peptide Receptor Radionuclide Therapy (PRRT) may induce long-term toxicity to the bone marrow (BM). The aim of this study was to analyze persistent dysfunction of the hematopoietic system after PRRT with (177)Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: The incidence and course of persistent hematological dysfunction (PHD) was analyzed in 274 (=GEP-NET) out of 367 patients with somatostatin receptor-positive tumors. PHD was defined as diagnosis of Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN) or otherwise unexplained cytopenia (for more than 6 months)...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28774729/-thrombotic-microangiopathy-and-cancer
#13
Rania Kheder El-Fekih, Clément Deltombe, Hassan Izzedine
Thrombotic microangiopathy (TMA) is a group of disorders characterized by mechanical hemolytic anemia with thrombocytopenia and an ischemic organic lesion of variable and potentially fatal importance affecting mostly the kidneys and the brain with histologically a disseminated and occlusive microvasculopathy. The incidence of TMA represents 15% of acute kidney failure in oncological setting, largely due to the introduction of anti-angiogenic agents over the past decade. It may be more rarely related to cancer itself...
July 31, 2017: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/28766263/a-phase-ii-study-of-combination-therapy-with-oral-s-1-and-cisplatin-in-elderly-patients-with-advanced-gastric-cancer
#14
Yusuke Sasaki, Satoru Iwasa, Shunsuke Okazaki, Masahiro Goto, Yasushi Kojima, Atsushi Naganuma, Kengo Nagashima, Yushi Nagai, Hidekazu Hirano, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Tetsuya Hamaguchi
BACKGROUND: A combination of S-1 and cisplatin is recognized as one of the standard first-line chemotherapy regimens for patients with advanced gastric cancer. However, demographic analyses of pivotal phase III studies have showed that only a minority of treated patients were aged 76 years or older. The purpose of this phase II study was to evaluate the safety and efficacy of combination therapy with S-1 and cisplatin in elderly patients with chemotherapy-naive advanced gastric cancer...
August 1, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28764748/a-phase-i-trial-of-ganetespib-in-combination-with-paclitaxel-and-trastuzumab-in-patients-with-human-epidermal-growth-factor-receptor-2-her2-positive-metastatic-breast-cancer
#15
Komal Jhaveri, Rui Wang, Eleonora Teplinsky, Sarat Chandarlapaty, David Solit, Karen Cadoo, James Speyer, Gabriella D'Andrea, Sylvia Adams, Sujata Patil, Sofia Haque, Tara O'Neill, Kent Friedman, Francisco J Esteva, Clifford Hudis, Shanu Modi
BACKGROUND: Targeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance. Preclinical data suggest that HSP90 inhibition is synergistic with taxanes with the potential for significant clinical activity. We therefore tested ganetespib, a HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-positive metastatic breast cancer...
August 2, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28761968/a-retrospective-study-of-amrubicin-monotherapy-for-the-treatment-of-relapsed-small-cell-lung-cancer-in-elderly-patients
#16
Hisao Imai, Tomohide Sugiyama, Tomohiro Tamura, Hiroyuki Minemura, Kyoichi Kaira, Kenya Kanazawa, Hiroshi Yokouchi, Takashi Kasai, Takayuki Kaburagi, Koichi Minato
PURPOSE: Amrubicin is one of the most active chemotherapeutic drugs for small cell lung cancer (SCLC). Previous studies reported its effectiveness and severe hematological toxicity. However, the efficacy of amrubicin monotherapy in elderly patients with SCLC has not been described. The objective of this study was to investigate the feasibility of amrubicin monotherapy in elderly patients and its efficacy for relapsed SCLC. METHODS: A retrospective cohort study design was used...
July 31, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28742500/adverse-effects-of-androgen-deprivation-therapy-in-patients-with-prostate-cancer-focus-on-metabolic-complications
#17
REVIEW
Vasileios Tzortzis, Michael Samarinas, Ioannis Zachos, Athanasios Oeconomou, Louis L Pisters, Alexandra Bargiota
Prostate cancer is the most common cancer among men and androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of the treatment of prostate cancer is inhibition of testosterone production which interrupts testosterone-induced growth of the prostate tumor. The dramatic decrease in testosterone levels, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia, and anemia, provoke vasomotor flushing, and generally affect the quality of life...
April 2017: Hormones: International Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28736507/national-mortality-burden-due-to-communicable-non-communicable-and-other-diseases-in-ethiopia-1990-2015-findings-from-the-global-burden-of-disease-study-2015
#18
Awoke Misganaw, Tilahun N Haregu, Kebede Deribe, Gizachew Assefa Tessema, Amare Deribew, Yohannes Adama Melaku, Azmeraw T Amare, Semaw Ferede Abera, Molla Gedefaw, Muluken Dessalegn, Yihunie Lakew, Tolesa Bekele, Mesoud Mohammed, Biruck Desalegn Yirsaw, Solomon Abrha Damtew, Kristopher J Krohn, Tom Achoki, Jed Blore, Yibeltal Assefa, Mohsen Naghavi
BACKGROUND: Ethiopia lacks a complete vital registration system that would assist in measuring disease burden and risk factors. We used the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) estimates to describe the mortality burden from communicable, non-communicable, and other diseases in Ethiopia over the last 25 years. METHODS: GBD 2015 mainly used cause of death ensemble modeling to measure causes of death by age, sex, and year for 195 countries...
2017: Population Health Metrics
https://www.readbyqxmd.com/read/28736506/national-disability-adjusted-life-years-dalys-for-257-diseases-and-injuries-in-ethiopia-1990-2015-findings-from-the-global-burden-of-disease-study-2015
#19
Awoke Misganaw, Yohannes Adama Melaku, Gizachew Assefa Tessema, Amare Deribew, Kebede Deribe, Semaw Ferede Abera, Muluken Dessalegn, Yihunie Lakew, Tolesa Bekele, Tilahun N Haregu, Azmeraw T Amare, Molla Gedefaw, Mesoud Mohammed, Biruck Desalegn Yirsaw, Solomon Abrha Damtew, Tom Achoki, Jed Blore, Kristopher J Krohn, Yibeltal Assefa, Mahlet Kifle, Mohsen Naghavi
BACKGROUND: Disability-adjusted life years (DALYs) provide a summary measure of health and can be a critical input to guide health systems, investments, and priority-setting in Ethiopia. We aimed to determine the leading causes of premature mortality and disability using DALYs and describe the relative burden of disease and injuries in Ethiopia. METHODS: We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) for non-fatal disease burden, cause-specific mortality, and all-cause mortality to derive age-standardized DALYs by sex for Ethiopia for each year...
2017: Population Health Metrics
https://www.readbyqxmd.com/read/28732542/national-disability-adjusted-life-years-dalys-for-257-diseases-and-injuries-in-ethiopia-1990-2015-findings-from-the-global-burden-of-disease-study-2015
#20
Awoke Misganaw, Yohannes Adama Melaku, Gizachew Assefa Tessema, Amare Deribew, Kebede Deribe, Semaw Ferede Abera, Muluken Dessalegn, Yihunie Lakew, Tolesa Bekele, Tilahun N Haregu, Azmeraw T Amare, Molla Gedefaw, Mesoud Mohammed, Biruck Desalegn Yirsaw, Solomon Abrha Damtew, Tom Achoki, Jed Blore, Kristopher J Krohn, Yibeltal Assefa, Mahlet Kifle, Mohsen Naghavi
BACKGROUND: Disability-adjusted life years (DALYs) provide a summary measure of health and can be a critical input to guide health systems, investments, and priority-setting in Ethiopia. We aimed to determine the leading causes of premature mortality and disability using DALYs and describe the relative burden of disease and injuries in Ethiopia. METHODS: We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) for non-fatal disease burden, cause-specific mortality, and all-cause mortality to derive age-standardized DALYs by sex for Ethiopia for each year...
July 21, 2017: Population Health Metrics
keyword
keyword
34939
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"